MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Craig-Hallum 22nd Annual Institutional Investor Conference | Minneapolis, MN
1:1 sessions: Wednesday, May 28, 2025
Goldman Sachs 46th Annual Global Healthcare Conference | Miami, FL
1:1 sessions: Wednesday, June 11, 2025
Northland Capital Growth Conference | Virtual
1:1 sessions: Wednesday, June 25, 2025
Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Goldman Sachs or Northland representative.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.69 |
| Daily Change: | 0.06 0.90 |
| Daily Volume: | 478,027 |
| Market Cap: | US$989.850M |
October 06, 2025 July 30, 2025 May 05, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
